Impact of bimekizumab on CANDEN spinal MRI inflammation and structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 results
Abstract
Objectives: To evaluate the impact of 2-year treatment with bimekizumab, a dual IL-17A and IL-17F inhibitor, on spinal MRI inflammatory and structural lesions in patients with radiographic axial spondyloarthritis (r-axSpA) in BE MOBILE 2 and its open-label extension (OLE) using Canada-Denmark (CANDEN) scoring.
Methods: Patients in BE MOBILE 2 and its OLE with spinal MRIs at baseline, weeks 16, 52 and 104 were included. MRIs were evaluated using CANDEN scores/subscores for inflammation, fat lesions, erosions and new bone formation; mean change from baseline (CfB) is reported. All data are observed case.
Results: Of 332 patients in BE MOBILE 2, 102 had MRIs eligible for CANDEN scoring at all four timepoints. Mean reductions from baseline in total inflammation score were observed with bimekizumab at week 16 (CfB: −7.3), with minimal further change at week 104 (−6.6). Largely similar patterns were observed in inflammation subscores to week 104, including the posterolateral inflammation subscore. In bimekizumab-randomized patients, the total fat lesions score increased from baseline to week 16 (CfB: 1.6), with minimal further change at week 104 (1.8). These increases were reflected in patients with baseline inflammation; those without baseline inflammation had minimal change at all timepoints. Minimal changes were observed in total erosions, and new bone formation scores.
Conclusions: In bimekizumab-treated patients with r-axSpA, comprehensive MRI CANDEN scoring showed reductions in spinal inflammation at all anatomical locations at week 16, sustained at 2 years, initial increases in fat lesions with minimal subsequent change and minimal changes in erosions and new bone formation.
Related
- Differentiation of axial spondyloarthritis-related lesions from degenerative lesions on Na[18F]Fluoride PET/CT in a longitudinal dataset of patients with radiographic axial spondyloarthritis
- Lower-Limb Muscle Architecture and Strength in Men with Radiographic Axial Spondyloarthritis: A Cross-Sectional Ultrasound Study
- Vigorous physical activity and physical function are strongly associated with better health in patients with long-standing radiographic axial spondyloarthritis
- Clinical Factors and Cumulative Smoking Burden Associated with Anti-TNF Switching in Radiographic Axial Spondyloarthritis: A Real-World Cohort Study
- Long‐Term Clinical and Radiographic Outcomes of Large Periapical Lesions Managed by Non‐Surgical and Surgical Endodontic Treatment: A Case Series
BibTeX
@article{maksymowych2026impact,
title = {{Impact of bimekizumab on CANDEN spinal MRI inflammation and structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 results}},
author = {Walter P Maksymowych and Robert G W Lambert and Victoria Navarro-Compán and Xenofon Baraliakos and Jason Coarse and Natasha de Peyrecave and Mikkel Østergaard},
journal = {Rheumatology (Oxford, England)},
year = {2026},
month = oct,
doi = {10.1093/rheumatology/keag484},
url = {https://doi.org/10.1093/rheumatology/keag484},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Impact of bimekizumab on CANDEN spinal MRI inflammation and structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 results
AU - Walter P Maksymowych
AU - Robert G W Lambert
AU - Victoria Navarro-Compán
AU - Xenofon Baraliakos
AU - Jason Coarse
AU - Natasha de Peyrecave
AU - Mikkel Østergaard
PY - 2026
DA - 2026/10/05
JO - Rheumatology (Oxford, England)
DO - 10.1093/rheumatology/keag484
UR - https://doi.org/10.1093/rheumatology/keag484
AB - Objectives: To evaluate the impact of 2-year treatment with bimekizumab, a dual IL-17A and IL-17F inhibitor, on spinal MRI inflammatory and structural lesions in patients with radiographic axial spondyloarthritis (r-axSpA) in BE MOBILE 2 and its open-label extension (OLE) using Canada-Denmark (CANDEN) scoring. Methods: Patients in BE MOBILE 2 and its OLE with spinal MRIs at baseline, weeks 16, 52 and 104 were included. MRIs were evaluated using CANDEN scores/subscores for inflammation, fat lesions, erosions and new bone formation; mean change from baseline (CfB) is reported. All data are observed case. Results: Of 332 patients in BE MOBILE 2, 102 had MRIs eligible for CANDEN scoring at all four timepoints. Mean reductions from baseline in total inflammation score were observed with bimekizumab at week 16 (CfB: −7.3), with minimal further change at week 104 (−6.6). Largely similar patterns were observed in inflammation subscores to week 104, including the posterolateral inflammation subscore. In bimekizumab-randomized patients, the total fat lesions score increased from baseline to week 16 (CfB: 1.6), with minimal further change at week 104 (1.8). These increases were reflected in patients with baseline inflammation; those without baseline inflammation had minimal change at all timepoints. Minimal changes were observed in total erosions, and new bone formation scores. Conclusions: In bimekizumab-treated patients with r-axSpA, comprehensive MRI CANDEN scoring showed reductions in spinal inflammation at all anatomical locations at week 16, sustained at 2 years, initial increases in fat lesions with minimal subsequent change and minimal changes in erosions and new bone formation.
SN - 1462-0324
SN - 1462-0332
ER -